Literature DB >> 12692607

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.

A J Peniket1, M C Ruiz de Elvira, G Taghipour, C Cordonnier, E Gluckman, T de Witte, G Santini, D Blaise, H Greinix, A Ferrant, J Cornelissen, N Schmitz, A H Goldstone.   

Abstract

The role of allogeneic bone marrow transplantation in lymphoma remains uncertain. We have analyzed 1185 allogeneic transplants for lymphoma reported to the EBMT registry between 1982 and 1998 and compared the results with those of 14687 autologous procedures performed over the same period. Patients receiving allogeneic transplants were subdivided according to histology: low-grade non-Hodgkin's lymphoma (NHL) 231 patients; intermediate-grade NHL 147 patients; high-grade NHL 255 patients; lymphoblastic NHL 314 patients; Burkitt's lymphoma 71 patients; and Hodgkin's disease 167 patients. These patients received allogeneic transplants as their first transplant procedure. Actuarial overall survival (OS) at 4 years from transplantation was: low-grade NHL 51.1%; intermediate-grade NHL 38.3%; high-grade NHL 41.2%; lymphoblastic lymphoma 42.0% years; Burkitt's lymphoma 37.1%; and Hodgkin's disease 24.7% years. These outcomes are relatively poor because of the high procedure-related mortality associated with these procedures, particularly in patients with Hodgkin's disease (51.7% actuarial procedure-related mortality at 4 years). Multivariate analysis showed that for all lymphomas apart from Hodgkin's disease, status at transplantation significantly affected outcome. A matched analysis was performed: for all categories of lymphoma, OS was better for autologous than for allogeneic transplantation. Relapse rate was better in the allogeneic group for low-, intermediate- and high-grade, and lymphoblastic NHL. It was equivalent for Burkitt's lymphoma and worse in the allogeneic group for Hodgkin's disease. Allogeneic transplantation appears to be superior to autologous procedures in terms of producing a lower relapse rate. The toxicity of allogeneic procedures must however be reduced before this translates into an improvement in OS.

Entities:  

Mesh:

Year:  2003        PMID: 12692607     DOI: 10.1038/sj.bmt.1703891

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  78 in total

Review 1.  Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Koen van Besien
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

Review 2.  Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.

Authors:  John G Gribben; Chitra Hosing; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

3.  Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Authors:  Marcie R Tomblyn; Marian Ewell; Christopher Bredeson; Brad S Kahl; Stacey A Goodman; Mary M Horowitz; Julie M Vose; Robert S Negrin; Ginna G Laport
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-10       Impact factor: 5.742

Review 4.  Adoptive immunotherapy for Hodgkin's lymphoma.

Authors:  Alana A Kennedy-Nasser; Catherine M Bollard; Cliona M Rooney
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 5.  Investigational strategies in autologous stem cell transplantation for follicular lymphoma.

Authors:  Oliver Weigert; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann; Christian Buske
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

6.  Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, disease, and treatment characteristics.

Authors:  Marcia Grant; Liz Cooke; Anna Cathy Williams; Smita Bhatia; Leslie Popplewell; Gwen Uman; Stephen Forman
Journal:  Support Care Cancer       Date:  2012-02-09       Impact factor: 3.603

7.  Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.

Authors:  Yoshikiyo Ito; Toshihiro Miyamoto; Tomohiko Kamimura; Ken Takase; Hideho Henzan; Yasuo Sugio; Koji Kato; Yuju Ohno; Tetsuya Eto; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-09-17       Impact factor: 2.490

8.  Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.

Authors:  Nishitha M Reddy; Olalekan Oluwole; John P Greer; Brian G Engelhardt; Madan H Jagasia; Bipin N Savani
Journal:  Exp Hematol       Date:  2013-10-02       Impact factor: 3.084

9.  Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma.

Authors:  Naoto Fujita; Ryoji Kobayashi; Yoshiko Atsuta; Fuminori Iwasaki; Junji Suzumiya; Yoji Sasahara; Masami Inoue; Katsuyoshi Koh; Tsukasa Hori; Hiroaki Goto; Tatsuo Ichinohe; Yoshiko Hashii; Koji Kato; Ritsuro Suzuki; Tetsuo Mitsui
Journal:  Int J Hematol       Date:  2019-01-30       Impact factor: 2.490

10.  A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

Authors:  Hillard M Lazarus; Mei-Jie Zhang; Jeanette Carreras; Brandon M Hayes-Lattin; Asli Selmin Ataergin; Jacob D Bitran; Brian J Bolwell; César O Freytes; Robert Peter Gale; Steven C Goldstein; Gregory A Hale; David J Inwards; Thomas R Klumpp; David I Marks; Richard T Maziarz; Philip L McCarthy; Santiago Pavlovsky; J Douglas Rizzo; Thomas C Shea; Harry C Schouten; Shimon Slavin; Jane N Winter; Koen van Besien; Julie M Vose; Parameswaran N Hari
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-04       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.